L-glutamine Therapy Making Strides in Diabetes Treatment
pharmatechoutlook

L-glutamine Therapy Making Strides in Diabetes Treatment

By Pharma Tech Outlook | Wednesday, July 03, 2019

Dr. Yutaka Niihara, CEO and Chairman, Emmaus Life Sciences

Improvements found in L-glutamine therapy are hoping to add a safe and effective treatment for diabetes.

FREMONT, CA: “While working with sickle cell patients using L-glutamine, we have discovered numerous other potential benefits of L-glutamine.  Some were learned from the literature and some from our experience.  Among them, we have found particular interests in two areas — one in diabetes and diverticulosis.  We observed improvements in diabetes markers just with L-glutamine therapy.  We believe that glucagon-like protein may be affected to bring out positive changes. We hope this may add a safe and effective treatment to currently available diabetes regimen.  We had a similar experience with diverticulosis.  We hypothesize that L-glutamine’s ability to strengthen intestinal muscle and to rejuvenate mucosal membrane may lead to healing of diverticulosis. We are preparing to initiate a pilot trial for the treatment of diverticulosis,” remarks Dr. Yutaka Niihara, CEO and Chairman of Emmaus Life Sciences announcing its use of pharmaceutical-grade L-glutamine in a clinical study to decide its efficacy in lowering blood sugar in patients with type II diabetes.

Diabetes is the under main focus for Emmaus as it looks to widen the therapeutic application of PGLG. Type II diabetes is the most common disease, and having evidence that PGLG could lower blood sugar would have significant implications in safe and effective treatment for patients. Emmaus is also collaborating with the Straub Medical Center to better understand the role of PGLG in the treatment of diabetes.

The mission of Emmaus Life Sciences is to empower people’s lives through the discovery, development, and commercialization of innovative treatments and therapies. The company focuses on rare and orphan diseases, such as SCD (Sickle Cell Disease). Emmaus is also extending its efforts to include conditions and illnesses affecting larger populations, such as diverticulosis.

Check This Out: Top Diabetes Care Companies

Weekly Brief